Physician profile
Michael A Gardyn
NPI 1205981867
$2,381.69
in general payments reported to CMS, 2019-2025
29 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $127 · 2021: $572 · 2022: $676 · 2023: $328 · 2024: $193 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $973.25 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $165.15 | 2019-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $135.04 | 2019-2023 | Ztlido |
| Protega Pharmaceutials INC | $129.83 | 2023 | Roxybond |
| Pfizer INC. | $128.28 | 2019-2024 | |
| Amgen INC. | $97.56 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $93.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $72.94 | 2020-2021 | |
| Lilly USA, LLC | $69.62 | 2022 | |
| Pacira Therapeutics, INC. | $53.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.60 | 2019 | |
| Daiichi Sankyo INC. | $42.39 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $40.98 | 2025 | |
| Electronic Waveform Lab, INC. | $37.44 | 2022 | |
| Allergan, INC. | $32.00 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $27.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.64 | 2022 | |
| Redhill Biopharma INC. | $25.87 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.16 | 2020 | |
| Saluda Medical Americas, INC. | $19.95 | 2024 | Evoke |
| Ibsa Pharma INC. | $19.23 | 2021 | |
| Shionogi INC | $18.73 | 2019 | |
| Fidia Pharma USA INC. | $17.63 | 2021 | |
| Nevro Corp. | $17.07 | 2022 | |
| Assertio Therapeutics, INC. | $15.02 | 2019 | |
| Boston Scientific Corporation | $14.71 | 2023 | Wavewriter Alpha Prime 16 |
| Horizon Therapeutics Plc | $14.41 | 2020 | |
| Djo, LLC | $12.46 | 2019 | |
| Forte Bio-Pharma LLC | $10.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gardyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.